About our research
Indevex has invested more than 15 years into basic and clinical research in order to develop a clinical treatment in Medical Nutritional Therapy and fight the metabolic syndrome and its consequences, such as diabetes and obesity. The Macronutrient Preload Method is based on the defined and standardized composition of nutrients, allowing studies to be as repeatable as for conventional drugs, but consists entirely of the highest quality naturally balanced nutrition. Macronutrient Preload was primarily developed by a Canadian doctor in late 1990s as a strict diet for children with cognitive disorders. On that basis, Indevex has developed a treatment and products together with, inter alia, Lund University and the University of Sydney, Australia, documented and patented the formula’s (Nutritional Glycemic Control, NGC) effect on the metabolic syndrome. The combination of natural nutrients in the formula is carefully determined, allowing to add to the system essential nutrients and a complete set of proteins, structured fat acids and complex carbohydrates – all based on natural raw materials. The recommended daily allowance (RDA) of essential aminoacids, according to the WHO guidelines, is only three daily formula intakes. The products also contain carbohydrates and dietary fiber that ensures a low glycemic load, leading to a low and stable blood sugar response with a good feeling of saturation. All raw products come from natural sources such as pea, medical grade eggs, with an optimized balance of Omega 3/6; whey, rose hips, apple and sugar beet fiber. Each step in the production of formula follows the strictest production standards, raw materials are processed only mechanically and are completely free of any added chemicals and GMOs. The basic formula is produced in Sweden under strict control. More than 15 years of studies and end user experiences have led us to a point where the effect is documented with the controlled clinical studies results, the so-called evidence-based medicine. Since 2012, the company started to conduct studies at the leading universities internationally with a focus on clinical evaluation of products, mainly for diabetes, but also for other metabolic syndrome effects.
Indevex has previously conducted around twenty observations and pilot studies since 2001, which demonstrated a significant effect on blood sugar content, HbA1c and insulin, triglycerides and cholesterol, systolic and diastolic blood pressures, weight, BMI and waistlines.
The studies conducted on the company’s products Glycemic Index (GI) show that the formula has a low GI value (<55). Having a diet with low GI reduces the risk of Type 2 Diabetes and may reduce the need for medication in diabetes patients. Indevex has two published studies and a third study is soon to be approved for publication.
The first study is a before-and-after study on patients with Type 2 Diabetes Mellitus. They took the company’s products with significant results in postprandial blood sugar response. The study can be downloaded in its entirety below.
The second study is a randomized placebo-controlled study of women with Gestational Diabetes (GDM), who received the company’s products after being diagnosed. Significant results were achieved, including on fasting plasma glucose and postprandial blood glucose response. The study can be downloaded in its entirety below.
The third study, which is yet to be published, is a randomized, placebo-controlled study of women diagnosed with Gestational Diabetes (GDM). The study demonstrates significant results for important clinical factors. The study has been posted at ESPEN Copenhagen 2016. Extracts can be downloaded below.
The company has also been working to develop an overview of the current state of science concerning GDM. The overview can be downloaded here. It is continually updated as new evidence comes.
